Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial.

Zhang, Li; Ma, Shenglin; Song, Xiangqun; Han, Baohui; Cheng, Ying; Huang, Cheng; Yang, Shujun; Liu, Xiaoqing; Liu, Yunpeng; Lu, Shun; Wang, Jie; Zhang, Shucai; Zhou, Caicun; Zhang, Xiangwei; Hayashi, Nobuya; Wang, Mengzhao

Zhang, Li; Ma, Shenglin; Song, Xiangqun; Han, Baohui; Cheng, Ying; Huang, Cheng; Yang, Shujun; Liu, Xiaoqing; Liu, Yunpeng; Lu, Shun; Wang, Jie; Zhang, Shucai; Zhou, Caicun; Zhang, Xiangwei; Hayashi, Nobuya; Wang, Mengzhao.

Affiliation

Zhang L; Cancer Centre, Sun Yat-Sen University, Guangzhou, China. li-zhang@csco.org.cn

Lancet Oncol ; 13(5): 466-75, 2012 May.

Article in En | MEDLINE | ID: mdl-22512843

Subject(s)

Antineoplastic Agents/therapeutic use; Carcinoma, Non-Small-Cell Lung/drug therapy; Quinazolines/therapeutic use; Adult; Aged; Carcinoma, Non-Small-Cell Lung/pathology; Carcinoma, Non-Small-Cell Lung/secondary; Double-Blind Method; Female; Gefitinib; Humans; Male; Middle Aged; Survival Analysis; Treatment Outcome; Young Adult

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quinazolines / Carcinoma, Non-Small-Cell Lung / Antineoplastic Agents Type of study: Clinical_trials / Prognostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2012 Document type: Article Affiliation country: China

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google